At the time of writing, Pro Medicus shares are fetching $58.42 apiece, up 3.4%.
Pro Medicus share price rises on
- Revenue from customers increased 19.5% to $67.9 million
- Underlying profit before tax up 41% to $42.6 million compared to prior year
- Net profit after tax attributable to shareholders increased 33.7% to $30.9 million
- Fully franked final dividend of 8 cents per share declared, taking total dividends in FY21 to 15 cents per share
- Record number of new contracts announced during the year
- Company remains debt free, increasing cash and other financial assets to $61.8 million, up 42.4%
What happened in FY21 for Pro Medicus
It was another record financial year for the healthcare imaging company valued at a $5.98 billion market capitalisation. Pro Medicus was undeterred by the pandemic, delivering a significant 19.5% increase in revenue from customer contracts — taking the total to $67.9 million.
During the year, sales and implementations initiatives were at an all-time high, demonstrating the minimal impact COVID-19 restrictions had on the business. This enabled the company to cement several milestone contracts in FY21. Some of these include the $25 million 7 year deal with NYU Langone Health and the $40 million 7 year contract with Intermountain Healthcare.
Despite significant currency fluctuations, Pro Medicus’ bottom-line earnings came in at $30.9 million — representing an increase of 33.7% on the previous year.
The significant uptick in profit has allowed the board to declare a fully franked final dividend of 8 cents per share. This takes total FY21 dividends to 15 cents per share, giving an indicative yield of 0.26%.
What did management say?
Commenting on the result, Pro Medicus Chief Executive Officer Dr Sam Hupert said:
It was our most successful year by any measure. All of our key financial metrics headed in the right direction. We foreshadowed a step-up in revenue this year despite currency headwinds and lower numbers in the first quarter due to COVID restrictions and we have delivered on that. Margins continued to increase as did our cash and other financial assets. It was also our biggest year in terms of both sales and implementations, laying the
foundation for a further step-up in exam volumes in FY22
Additionally, regarding the company’s pipeline potential, Mr Hupert said:
Although we had a record year in terms of new contracts, our pipeline remains very healthy both in terms of quality and quantity. There is a good mix across the spectrum of opportunities; some cloud, some on-premise, some academic and some in the non-academic-IDN space as well as in the for-profit and private sector.
What’s next for Pro Medicus?
Pro Medicus did not specify any outlook or guidance for FY22. However, the company remains focused on expanding its customers through its pipeline. Notably, a number of opportunities are for more than one Visage product.
Additionally, Pro Medicus continues to develop products with its AI Accelerator program.
Pro Medicus share price snapshot
The Pro Medicus share price has returned an impressive 131% to shareholders over the past year. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) has climbed 22.8% during the same time frame.
Based on the current share price, Pro Medicus is trading on a 194 times price-to-earnings (P/E) ratio.